MedGenome is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases.
MedGenome is on a mission to improve global health by decoding the genetic information contained in an individual’s genome.
MedGenome was founded in 2013 by Sam Santhosh, alongside with Mahesh Pratapneni. The company is headquartered in Bangalore, Karnataka and Foster City, California.
MedGenome offers end-to-end solutions for next-generation sequencing based assays for a wide range of sample types (such as DNA, RNA, PBMCs, purified CD4 and CD8+ T-cells, splenocytes, TILs, T-cell lines and B-cells).
MedGenome has built proprietary solutions to enable pharma and biotech companies accelerate their early drug discovery pipeline as well as aid in biomarker discovery for their companion diagnostics programs.
MedGenome's proprietary cancer immunotherapy solution, OncoPept combines tumor-derived genomic and transcriptomic data to map the molecular features of the tumor and predict personalized cancer immunotherapy combinations with neoantigen vaccines for therapy.
MedGenome is backed by LeapFrog Investments, Sofina, Sequoia Capital, HDFC Ltd., Emerge Ventures and others. The company raised $55M in a Series D round on April 01, 2020. This brings MedGenome's total funding to $119M to date.